251008 BICHEDAM Strengthens BCD101 Clinical Competitiveness with Prof. Kiuk Jang Joining

BICHEDAM, a company specializing in natural product-based pharmaceuticals, announced that it has signed a joint clinical development research agreement with Haam Bio Co., Ltd. for the nocturnal leg cramp (NLC) treatment candidate, ‘BCD101’.

Through this agreement, Professor Kiuk Jang of the Department of Cardiology at Catholic University Seoul St. Mary’s Hospital has joined as the Principal Investigator (PI) for the upcoming clinical trial. Professor Jang is a cardiovascular disease specialist affiliated with the Department of Cardiology and the Cardiovascular and Cerebrovascular Hospital at Seoul St. Mary’s Hospital, and he actively participates in the Korean Society of Cardiology, the Korean Society of Interventional Cardiology, as well as multiple multicenter clinical trials.

With Professor Jang’s participation, BICHEDAM and Haam Bio plan to actively advance preparations for the Phase 2 clinical trial next year. They also expect to strengthen the foundation for patient recruitment and study execution by leveraging the St. Mary’s Hospital network.

Under this agreement, the two companies will establish a research committee to formulate clinical strategies and develop a roadmap extending through the product approval stage.

In addition, while focusing on BCD101, the companies plan to actively explore expanded indications beyond the ongoing NLC trial, including microvascular angina (MVA) and other unmet cardiovascular conditions. This strategy aims to broaden the clinical applications of the natural product-based ROCK inhibitor and reinforce the foundation for global market entry.

Hobin Moon, CEO of BICHEDAM, stated, “With Phase 1 progressing smoothly, having Professor Kiuk Jang join as PI during preparations for Phase 2 is highly significant. Leveraging his expertise and network, we aim to secure global competitiveness in the unmet NLC market.”

Source: Maeil Shinmun https://www.imaeil.com/page/view/2025100811054349326